Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metyrapone for Cardiovascular Risk in Subclinical Cushing's Syndrome
NCT06801249Phase 4Recruiting
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Feb 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metyrapone in Cushing's syndrome and Adrenal incidentaloma (AI) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Change in Number and/or Dosage of Antihypertensive Drugs at 12 months. Started Feb 2021; status: recruiting.
02
Drugs
metyrapone
03
Conditions
Cushing's syndromeAdrenal incidentaloma (AI)
Beyond the preview
Go deeper on NCT06801249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801249.